Details for Patent: 12,285,430

Which drugs does patent 12,285,430 protect, and when does it expire?

Patent 12,285,430 protects ROMVIMZA and is included in one NDA.

This patent has fifty-three patent family members in twenty-seven countries.

Summary for Patent: 12,285,430

Title:	Methods of treating disorders using CSF1R inhibitors
Abstract:	Described herein are methods of treating cancers and other tumors related to the decreased proliferation, the depletion, or the repolarization of tumor-associated macrophages (TAMs) and treatment of associated disorders, including tenosynovial giant cell tumor (TGCT) and diffuse-type tenosynovial giant cell tumor (DTGCT).
Inventor(s):	Daniel L. Flynn, Bryan D. Smith, Rodrigo Ruiz Soto, Keisuke Kuida
Assignee:	Deciphera Pharmaceuticals LLC
Application Number:	US18/140,942
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 12,285,430

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Deciphera Pharms	ROMVIMZA	vimseltinib	CAPSULE;ORAL	219304-001	Feb 14, 2025		RX	Yes	No						TREATMENT OF TENOSYNOVIAL GIANT CELL TUMOR
Deciphera Pharms	ROMVIMZA	vimseltinib	CAPSULE;ORAL	219304-002	Feb 14, 2025		RX	Yes	No						TREATMENT OF TENOSYNOVIAL GIANT CELL TUMOR
Deciphera Pharms	ROMVIMZA	vimseltinib	CAPSULE;ORAL	219304-003	Feb 14, 2025		RX	Yes	Yes						TREATMENT OF TENOSYNOVIAL GIANT CELL TUMOR

International Family Members for US Patent 12,285,430

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	3902547		C20260007	Finland
European Patent Office	3902547		PA2026508	Lithuania
European Patent Office	3902547		202640007	Slovenia
Argentina	117742
Australia	2019416117